# Indomo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indomo

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.indomotx.com/
- Total disclosed funding: $22M
- Latest round: Series B (Oct 29, 2025)
- Investors on record: 3

## About

Indomo, based in San Francisco, US, focuses on developing innovative device-enabled therapeutics to enhance access to quality healthcare, particularly in dermatology.Indomo specializes in innovative therapeutics aimed at improving access to healthcare. The company was formed with a focus on developing the ClearPen™ System, which allows patients to self-administer acne treatment. Indomo is headquartered in San Francisco, US, and raised USD 25.00 mn in funding on October 29, 2025, led by investors including Atomic Management, Foresite Capital, and Polaris Partners. The total amount raised by the company to date stands at USD 25.00 mn.Indomo specializes in innovative device-enabled therapeutics aimed at improving access to quality healthcare. The company's primary offering is the ClearPen™ System, which combines their drug candidate, DT-001, with a novel intradermal self-injection device. This system empowers patients to administer intralesional triamcinolone acetonide injections for treating inflammatory acne lesions at home, addressing a critical gap in dermatological care. Indomo's products are currently in development and target patients with moderate to severe acne lesions, particularly in regions where access to in-office treatments is limited. The American Academy of Dermatology supports intralesional injections as a first-line treatment, emphasizing the potential of Indomo's offerings in markets with significant acne treatment needs.Indomo's revenue model focuses on the commercialization of the ClearPen™ System. The company envisions a direct-to-consumer transaction structure that enables patients to purchase the device and the accompanying drug on an as-needed basis. This model allows for flexibility in self-administration outside clinical settings, enhancing adherence. Transaction types may include one-time purchases or subscription plans for ongoing supplies of the device and drug. While specific pricing details are not disclosed, the model is designed to attract a diverse customer base, including individual patients seeking acne treatment. With the growing demand for at-home healthcare solutions, Indomo is positioned to benefit from the increasing trend towards self-administered therapies in dermatology.In October 2025, Indomo secured USD 25.00 mn in venture funding to support the development of at-home acne treatment technology and expand access to dermatology care. The funding will be utilized to enhance the ClearPen™ System and potentially introduce new products aimed at improving treatment adherence. Additionally, the company plans to explore expansion into international markets where access to dermatological services is limited, with specific timelines yet to be defined. This strategic investment aims to bolster Indomo's capabilities in addressing the needs of patients seeking convenient and effective acne treatments.

## Funding rounds

- Series B, Oct 29, 2025, $22M — Polaris Partners, Foresite Capital, Atomic Management

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Atomic Management (https://capitalatlas.ai/funds/atomic-management) — Series B